4164 Discovery Building
330 N Orchard St
Madison, WI 53715-1119
B.S., Cornell University
M.Phil., University of Cambridge (U.K.)
Ph.D., University of California-Berkeley
Postdoctoral, Whitehead Institute-MIT/Harvard University
Stem cell biology, genome engineering and biomaterials expertise to ask unique questions about human biology and disease
We utilize quantitative and bioengineering methods to advance the next generation of cell and gene therapies.
CRISPR-Cas9, nanoparticle delivery
We develop new tools and insights into the editing of the human genome. Projects include understanding DNA repair and nanoscale assembly of nucleic acids and novel nonviral polymeric delivery agents around protein-based CRISPR systems. We are advancing two projects in the NIH Somatic Cell Genome Editing Consortium.
Cell therapy manufacturing
Cells are living drugs that can be difficult to generate, scale-up, and quality control. Projects include monitoring and controlling the heterogeneity during gene modification and scale-up of stem cells and T cell immunotherapies (e.g., CAR T cells). We benefit from collaborations with the national Center for Cell Manufacturing.
Biomaterials + gene editing to generate new cell models
We are using customized biomaterials and genome editing to generate new human cell-based models of inherited disorders. Projects include correcting mutations within diseased cells and generate isogenic organoids that recapitulate morphogenesis and pathology seen in patients. This project exploits close collaboration with biologists and clinicians at the Waisman Center.
Cellular reprogramming can generate important resources for regenerative medicine and drug discovery, but can proceed inefficiently and in a stochastic manner. Projects include using engineered biomaterials and novel tools for epigenetic engineering.
Science and Technology Studies
We seek to understand the dynamic and heterogeneous processes by which novel bioengineered objects get embedded into law and policy. Outputs are designed to invoke reflection among practicing scientists on the social commitments behind their choices when engineering human cells, as well as to inform regulations, institutional obligations, and state policy. We leverage collaborations within Holtz STS Center, Bio+Society Collaboratory, and Forum on Regenerative Medicine.
Areas of Expertise
- Personalized Medicine
- Synthetic & Systems Biology